Incyte Corporation (INCY) PB Ratio: 3.66
Is Incyte Corporation’s P/B ratio high or low?
Incyte Corporation's P/B ratio of 3.66 is in line with its 5-year average of 3.96, around the middle of its 5-year range (2.19–7.06).
8.70% below its 12-month average of 4.01.
INCY PB Ratio Chart
INCY Average PB Ratio Chart
INCY Current vs Average PB Ratio Chart
INCY PB Ratio Metrics
PB RATIO
3.66
PB RATIO AVG TTM
4.01
PB RATIO AVG 3Y
3.59
PB RATIO AVG 5Y
3.90
PB RATIO AVG 10Y
5.94
PB RATIO AVG 15Y
N/A
PB RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.70%
CURRENT VS 3Y AVG
+2.03%
CURRENT VS 5Y AVG
-6.22%
CURRENT VS 10Y AVG
-38.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
INCY Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 3.66 | 4.01 | 3.59 | 3.90 |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 2.43 | 2.60 | 2.40 | 2.24 |
| Viatris Inc. (VTRS)vs › | $17.90B | 1.23 | 0.95 | 0.75 | 0.73 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 1.36 | 1.47 | 1.74 | 1.90 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 3.27 | 3.17 | 3.48 | 3.78 |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 4.29 | 3.25 | 2.69 | 2.61 |
| BioNTech SE (BNTX)vs › | $22.98B | 1.06 | 1.14 | 1.16 | 2.40 |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | N/A | 1966.63 | 623.56 | 375.27 |
| Waters Corporation (WAT)vs › | $23.17B | 1.91 | 8.07 | 13.74 | 31.93 |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 3.48 | 5.75 | 6.72 | 8.94 |
P/B vs. its own history
At 3.66, P/B is cheaper than usual, sitting higher than 15% of its 13-year history.
13-year low
2.19
median
7.19
13-year high
444.38
Book Value Analysis
P/B Ratio
3.66
Market Price / Book Value per Share
Incyte Corporation PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation PB Ratio FAQ
- What is the P/B ratio for Incyte Corporation (INCY)?
- The P/B ratio for INCY stock is 3.66.
- Is Incyte Corporation's P/B ratio high or low?
- Incyte Corporation's P/B ratio of 3.66 is in line with its 5-year average of 3.96, around the middle of its 5-year range (2.19–7.06).
- What is the TTM average P/B ratio for Incyte Corporation (INCY)?
- The TTM average P/B ratio for INCY stock is 4.01.
- What is the 3Y average P/B ratio for Incyte Corporation (INCY)?
- The 3Y average P/B ratio for INCY stock is 3.59.
- What is the 5Y average P/B ratio for Incyte Corporation (INCY)?
- The 5Y average P/B ratio for INCY stock is 3.90.
- What is the 10Y average P/B ratio for Incyte Corporation (INCY)?
- The 10Y average P/B ratio for INCY stock is 5.94.
Incyte Corporation PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-18 | 3.66 |
| 2026-06-17 | 3.69 |
| 2026-06-16 | 3.72 |
| 2026-06-15 | 3.80 |
| 2026-06-12 | 4.04 |
| 2026-06-11 | 4.02 |
| 2026-06-10 | 3.93 |
| 2026-06-09 | 3.85 |
| 2026-06-08 | 3.75 |
| 2026-06-05 | 3.81 |
| 2026-06-04 | 3.77 |
| 2026-06-03 | 3.65 |
| 2026-06-02 | 3.44 |
| 2026-06-01 | 3.56 |
| 2026-05-29 | 3.60 |
| 2026-05-28 | 3.63 |
| 2026-05-27 | 3.63 |
| 2026-05-26 | 3.62 |
| 2026-05-22 | 3.62 |
| 2026-05-21 | 3.63 |
| 2026-05-20 | 3.62 |
| 2026-05-19 | 3.56 |
| 2026-05-18 | 3.55 |
| 2026-05-15 | 3.55 |
| 2026-05-14 | 3.64 |
| 2026-05-13 | 3.68 |
| 2026-05-12 | 3.69 |
| 2026-05-11 | 3.74 |
| 2026-05-08 | 3.67 |
| 2026-05-07 | 3.64 |
| 2026-05-06 | 3.72 |
| 2026-05-05 | 3.63 |
| 2026-05-04 | 3.62 |
| 2026-05-01 | 3.61 |
| 2026-04-30 | 3.55 |
| 2026-04-29 | 3.69 |
| 2026-04-28 | 3.64 |
| 2026-04-27 | 3.79 |
| 2026-04-24 | 3.75 |
| 2026-04-23 | 3.78 |
| 2026-04-22 | 3.83 |
| 2026-04-21 | 3.81 |
| 2026-04-20 | 3.84 |
| 2026-04-17 | 3.88 |
| 2026-04-16 | 3.78 |
| 2026-04-15 | 3.85 |
| 2026-04-14 | 3.87 |
| 2026-04-13 | 3.79 |
| 2026-04-10 | 3.81 |
| 2026-04-09 | 3.84 |
| 2026-04-08 | 3.80 |
| 2026-04-07 | 3.71 |
| 2026-04-06 | 3.76 |
| 2026-04-02 | 3.80 |
| 2026-04-01 | 3.74 |
| 2026-03-31 | 3.73 |
| 2026-03-30 | 3.58 |
| 2026-03-27 | 3.58 |
| 2026-03-26 | 3.66 |
| 2026-03-25 | 3.65 |
| 2026-03-24 | 3.59 |
| 2026-03-23 | 3.58 |
| 2026-03-20 | 3.60 |
| 2026-03-19 | 3.68 |
| 2026-03-18 | 3.66 |
| 2026-03-17 | 3.73 |
| 2026-03-16 | 3.69 |
| 2026-03-13 | 3.67 |
| 2026-03-12 | 3.65 |
| 2026-03-11 | 3.75 |
| 2026-03-10 | 3.80 |
| 2026-03-09 | 3.85 |
| 2026-03-06 | 3.80 |
| 2026-03-05 | 3.86 |
| 2026-03-04 | 3.92 |
| 2026-03-03 | 3.89 |
| 2026-03-02 | 3.96 |
| 2026-02-27 | 4.01 |
| 2026-02-26 | 3.97 |
| 2026-02-25 | 3.96 |
| 2026-02-24 | 4.00 |
| 2026-02-23 | 4.00 |
| 2026-02-20 | 4.01 |
| 2026-02-19 | 4.03 |
| 2026-02-18 | 4.08 |
| 2026-02-17 | 4.01 |
| 2026-02-13 | 4.01 |
| 2026-02-12 | 3.99 |
| 2026-02-11 | 3.92 |
| 2026-02-10 | 3.96 |
| 2026-02-09 | 4.72 |
| 2026-02-06 | 4.69 |
| 2026-02-05 | 4.45 |
| 2026-02-04 | 4.44 |
| 2026-02-03 | 4.37 |
| 2026-02-02 | 4.45 |
| 2026-01-30 | 4.33 |
| 2026-01-29 | 4.38 |
| 2026-01-28 | 4.38 |
| 2026-01-27 | 4.48 |
| 2026-01-26 | 4.44 |
| 2026-01-23 | 4.42 |
| 2026-01-22 | 4.55 |
| 2026-01-21 | 4.53 |
| 2026-01-20 | 4.44 |
| 2026-01-16 | 4.60 |
| 2026-01-15 | 4.56 |
| 2026-01-14 | 4.59 |
| 2026-01-13 | 4.48 |
| 2026-01-12 | 4.60 |
| 2026-01-09 | 4.63 |
| 2026-01-08 | 4.59 |
| 2026-01-07 | 4.79 |
| 2026-01-06 | 4.62 |
| 2026-01-05 | 4.41 |
| 2026-01-02 | 4.39 |
| 2025-12-31 | 4.28 |
| 2025-12-30 | 4.28 |
| 2025-12-29 | 4.30 |
| 2025-12-26 | 4.34 |
| 2025-12-24 | 4.35 |
| 2025-12-23 | 4.37 |
| 2025-12-22 | 4.36 |
| 2025-12-19 | 4.45 |
| 2025-12-18 | 4.21 |
| 2025-12-17 | 4.23 |
| 2025-12-16 | 4.20 |
| 2025-12-15 | 4.27 |
| 2025-12-12 | 4.13 |
| 2025-12-11 | 4.16 |
| 2025-12-10 | 4.12 |
| 2025-12-09 | 4.12 |
| 2025-12-08 | 4.19 |
| 2025-12-05 | 4.44 |
| 2025-12-04 | 4.35 |
| 2025-12-03 | 4.40 |
| 2025-12-02 | 4.39 |
| 2025-12-01 | 4.42 |
| 2025-11-28 | 4.52 |
| 2025-11-26 | 4.58 |
| 2025-11-25 | 4.57 |
| 2025-11-24 | 4.60 |
| 2025-11-21 | 4.42 |
| 2025-11-20 | 4.41 |
| 2025-11-19 | 4.39 |
| 2025-11-18 | 4.50 |
| 2025-11-17 | 4.51 |
| 2025-11-14 | 4.51 |
| 2025-11-13 | 4.56 |
| 2025-11-12 | 4.69 |
| 2025-11-11 | 4.68 |
| 2025-11-10 | 4.59 |
| 2025-11-07 | 4.59 |
| 2025-11-06 | 4.56 |
| 2025-11-05 | 4.58 |
| 2025-11-04 | 4.46 |
| 2025-11-03 | 4.40 |
| 2025-10-31 | 4.05 |
| 2025-10-30 | 4.01 |
| 2025-10-29 | 3.91 |
| 2025-10-28 | 3.97 |
| 2025-10-27 | 4.44 |
| 2025-10-24 | 4.35 |
| 2025-10-23 | 4.26 |
| 2025-10-22 | 4.20 |
| 2025-10-21 | 4.16 |
| 2025-10-20 | 4.11 |
| 2025-10-17 | 4.17 |
| 2025-10-16 | 4.16 |
| 2025-10-15 | 4.20 |
| 2025-10-14 | 4.10 |
| 2025-10-13 | 4.04 |
| 2025-10-10 | 3.99 |
| 2025-10-09 | 4.04 |
| 2025-10-08 | 4.07 |
| 2025-10-07 | 4.15 |
| 2025-10-06 | 4.16 |
| 2025-10-03 | 4.14 |
| 2025-10-02 | 4.11 |
| 2025-10-01 | 4.13 |
| 2025-09-30 | 4.04 |
| 2025-09-29 | 4.00 |
| 2025-09-26 | 3.94 |
| 2025-09-25 | 3.89 |
| 2025-09-24 | 4.01 |
| 2025-09-23 | 4.03 |
| 2025-09-22 | 4.04 |
| 2025-09-19 | 4.12 |
| 2025-09-18 | 4.10 |
| 2025-09-17 | 4.04 |
| 2025-09-16 | 4.00 |
| 2025-09-15 | 3.96 |
| 2025-09-12 | 3.96 |
| 2025-09-11 | 4.11 |
| 2025-09-10 | 4.11 |
| 2025-09-09 | 4.08 |
| 2025-09-08 | 4.12 |
| 2025-09-05 | 4.13 |
| 2025-09-04 | 4.07 |
| 2025-09-03 | 4.14 |
| 2025-09-02 | 4.10 |
| 2025-08-29 | 4.03 |
| 2025-08-28 | 3.99 |
| 2025-08-27 | 4.04 |
| 2025-08-26 | 4.00 |
| 2025-08-25 | 4.04 |
| 2025-08-22 | 4.05 |
| 2025-08-21 | 4.12 |
| 2025-08-20 | 4.11 |
| 2025-08-19 | 4.07 |
| 2025-08-18 | 4.05 |
| 2025-08-15 | 4.14 |
| 2025-08-14 | 4.11 |
| 2025-08-13 | 4.09 |
| 2025-08-12 | 3.89 |
| 2025-08-11 | 3.77 |
| 2025-08-08 | 3.74 |
| 2025-08-07 | 3.73 |
| 2025-08-06 | 3.70 |
| 2025-08-05 | 3.70 |
| 2025-08-04 | 3.72 |
| 2025-08-01 | 3.60 |
| 2025-07-31 | 3.57 |
| 2025-07-30 | 3.70 |
| 2025-07-29 | 3.69 |
| 2025-07-28 | 3.79 |
| 2025-07-25 | 3.79 |
| 2025-07-24 | 3.81 |
| 2025-07-23 | 3.82 |
| 2025-07-22 | 3.72 |
| 2025-07-21 | 3.64 |
| 2025-07-18 | 3.67 |
| 2025-07-17 | 3.73 |
| 2025-07-16 | 3.74 |
| 2025-07-15 | 3.69 |
| 2025-07-14 | 3.78 |
| 2025-07-11 | 3.71 |
| 2025-07-10 | 3.80 |
| 2025-07-09 | 3.71 |
| 2025-07-08 | 3.66 |
| 2025-07-07 | 3.64 |
| 2025-07-03 | 3.70 |
| 2025-07-02 | 3.68 |
| 2025-07-01 | 3.71 |
| 2025-06-30 | 3.68 |
| 2025-06-27 | 3.69 |
| 2025-06-26 | 3.83 |
| 2025-06-25 | 3.65 |
| 2025-06-24 | 3.73 |
| 2025-06-23 | 3.63 |
| 2025-06-20 | 3.70 |
| 2025-06-18 | 3.69 |
| 2025-06-17 | 3.72 |
| 2025-06-16 | 3.85 |
| 2025-06-13 | 3.66 |
| 2025-06-12 | 3.74 |
| 2025-06-11 | 3.72 |
| 2025-06-10 | 3.79 |
| 2025-06-09 | 3.78 |
| 2025-06-06 | 3.72 |
Showing the most recent 260 of 2,811 data points. The chart above shows the full history.
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury